Sentence examples for biologic active from inspiring English sources
The TGF- β1, M-CSF, and VEGF-A assays detect specifically the biologic active form of the protein.
Endogen glycosides (digoxin-like immunoreactive substance (DLIS)), first described by Gruber et al. [ 15], are adrenocortical hormones, which are the biologic active inhibitors of Na+-K+-ATPase [ 16].
HMW-APM is currently suggested to represent the biologic active form of adiponectin [ 17] and was detected in control and T1D plasma when analysed by immunoblot.
Treatment with barrier membranes alone or in combination with different grafting materials, the use of biologic active substances such as enamel matrix proteins or growth factors have been shown to promote periodontal regeneration and to significantly improve the clinical outcomes evidenced by probing depth reduction, clinical attachment gain and defect fill [ 7].
Another important point, especially for inorganic chemicals, is that both environmental and biologic monitoring include the biologically active specie(s) of the chemical, for example, methyl mercury for assessing exposure to mercury after fish consumption (Needham et al. 2005a).
These results indicate that A. baumannii OMVs harbor biologically active virulence factors and enzymes, which can perform diverse biologic processes in host cells.
If the title contained the text "Manufacturers of the biological active substance…" we assumed the product was a biologic.
The conversion of latent-to-active transforming growth factor-β provides a pivotal mechanism for the regulation of the biologic activity of transforming growth factor-β.
The advent of the new millennium was associated with the availability of several new cytotoxic and biologic agents active in colorectal cancer.
Unlike traditional small-molecule chemotherapeutics, protein biologics promote active targeting of cancer cells by binding to cell-surface receptors and other markers specifically associated with or overexpressed on tumors versus healthy tissue.
The basis for our failures is unknown, but most assuredly relates to trial design issues, confounding by background medicines, and the multiplicity of active biologic pathways in this disease.
